Sino-Health Intelligence Conference (Xipu Summit) 2026 to Unveil AI-Driven Transformation of the Health Industry, Positioning as Global Counterpart to J.P. Morgan Healthcare Conference
August 12–17, the highly anticipated 2019 Westlake Conference will be grandly held in Boao, Hainan. As China’s prestigious health industry conference, it will bring together mainstream institutions from various sectors of the health industry, including pharmaceuticals, commerce, capital, research and development, technology, healthcare, health services, and financial insurance. Benchmarking against the J.P. Morgan Healthcare Conference, it aims to establish a second global health industry conference, providing forward-looking and systematic exchange of ideas and information for the industry.
Numerous distinguished guests will engage in intellectual exchanges around the conference theme, “Rebirth from the Ashes: Paving the Way to the Industry’s Future,” to clarify the direction of industrial development. Meanwhile, a series of high-value summits will be organized, bringing together professional capital institutions, leading enterprises, AI technologies, and other key stakeholders. These efforts aim to provide industry insiders and outsiders with multi-perspective, multi-level, and multi-dimensional insights into the future of the industry, thereby building a comprehensive ecosystem conference for the entire health industry chain.
“Clouds rise over the creek as the sun sets behind the pavilion; wind fills the tower, heralding the mountain rain.”
Driven by the combined forces of policy, capital, and technology, China’s pharmaceutical and health industry is undergoing a difficult adjustment from unchecked expansion to a return to rationality, with market reshuffling being the most prominent characteristic at present.
As the saying goes, “a single hair pulled affects the entire body.” Amidst industrial transformation, pharmaceutical manufacturers, distributors, and terminal channels within the ecosystem cannot remain on the sidelines.
As industrial development models shift, competitive landscapes evolve, and value propositions transform... how can one cut through the fog, look beyond the ever-changing surface of industries, and distill their underlying constants and developmental trends?
Where is health insurance policy headed? How can we grasp the new regulatory mindset from the revised Drug Administration Law? Will China’s health industry economy regain its strength or remain mired in a trough? What impact will China’s demographic trends have over the next decade? How will technological innovations such as 5G and quantum computing reshape the industry?
Facing the myriad issues shaping the future of the industry, renowned experts such as Fan Gang, Cai Jiangnan, and Ning Xiangdong will join forces to provide incisive insights at the 2019 WestPharm Conference.
Undoubtedly, the future pharmaceutical market will be divided into three segments: the commercial insurance market for prescription drugs, the public medical insurance market for prescription drugs, and the self-medication plus healthcare market. In light of this landscape, how can the industry and enterprises anchor their value propositions, identify value portfolios adapted to the future, and achieve value creation? This is a critical issue that must be clearly defined at this year’s Xipu Conference.
Based on the assessment of the aforementioned propositions, only by driving transformations in business models, profit models, management, and technology—from industry to enterprise, and from strategy to tactics—can the health industry and enterprises achieve a phoenix-like rebirth. How can this be accomplished? The 2019 West Lake Summit (Xipu Hui) will gather elites from all sectors for an intellectual exchange, illuminating the path forward with the sparks of ideas.
Meanwhile, benchmarking against the J.P. Morgan Healthcare Conference, CHC will curate a series of high-value summits, joining forces with industry authorities, insurance providers, health examination institutions, mainstream domestic and overseas secondary market investors, and AI R&D organizations in the health sector to gain multi-perspective, multi-level insights into the future of the industry.
Summit Value: In collaboration with China’s largest securities firm and renowned overseas brokerages, the summit brings together 50+ experts in health industry policy and market analysis, 300+ mainstream secondary-market investors from both overseas and China, and 100+ industry leaders from high-quality listed companies in innovative pharmaceuticals, premium healthcare, health management, pharmaceutical retail, medical devices, and other segments of the health industry. Together, we build a communication platform between outstanding listed health companies and the capital markets, interpret industrial shifts under new policies, gain insights into future development trends, identify investment hotspots, and uncover new value in health industry investments!
Summit Value: China’s health industry is currently at a historic juncture marked by profound environmental shifts and ecological restructuring. In the face of stark realities and a promising future, how can we gain insight into industry trends and adapt to the times? How can we balance development strategies and maintain the right pace? The strategic layouts of leading enterprises shape the landscape and set the direction. Since 2019, the “China Health Industry Leading Enterprises Innovation Strategy Launch” has become a flagship segment of the Westpu Conference (Xipu Hui), serving to clarify uncertainties and define directions during this transitional period, fulfilling the responsibilities of an industry pioneer, and driving industrial progress and evolution.
Summit Value: In an aging China, the challenge of controlling healthcare insurance costs is immense. As the prelude to the separation of prescribing and dispensing—a milestone event in the new healthcare reform—prescription outflow has seen limited momentum over the past two years, necessitating stronger multi-party collaboration. By pooling resources from leading chain pharmacies, pioneers in internet-based pharmaceutical services, branded prescription drug manufacturers, and authoritative pharmacy experts, we aim to collaboratively build an ecosystem for prescription outflow and accelerate the pace of the new healthcare reform.
Summit Value: Starting from practical application scenarios in clinical diagnosis and treatment, health management, and drug R&D, and guided by national policy directions and global R&D trends, we will jointly explore the R&D directions and target indications for artificial intelligence in the healthcare sector, thereby promoting technological innovation and practical implementation.
Summit Value: Implementing the industrial upgrade strategy centered on “meeting health needs,” addressing new dynamics in the marketing landscape, and leading the health industry into the era of digital marketing. The summit brings together over 400 senior marketing executives from branded pharmaceutical manufacturers and representatives from digital marketing agencies, staying attuned to industry trends and promoting efficient collaboration among resources across the industry chain.
August 12–17, Converge in Boao to Chart the Future of the Industry!